The significance of over-expression of epidermal growth factor receptor (EGFR) in pancreatic carcinoma is unclear. In this study, we examined the association between EGFR over-expression (membranous and cytoplasmic), the associated histopathologic features and clinical outcomes in post-resection pancreatic cancer patients. EGFR expression was determined immunohistochemically in 90 patients who underwent resection for pancreatic cancer. Cytoplasmic expression was considered positive if EGFR expression was seen in the cytoplasm in C10% of cells. Cell membrane staining was scored from 0 to 3?, with 2? and 3? being considered as membrane over-expression. Overall survival and progression-free survival were calculated using the Kaplan-Meier method, and survival curves were compared by the log-rank test. Out of 90 patients, 51 (57%) and 74 (68%) patients had membrane and cytoplasmic EGFR over-expression, respectively. There was a statistically significant correlation between cell membrane EGFR over-expression and lymph node positivity (P = 0.03). Patients with membrane EGFR over-expression had a shorter median progression-free survival (10.7 vs. 17.0 months, P = 0.02) and overall survival (15.9 months vs. 25.3 months, P = 0.17). Cytoplasmic EFGR over-expression was not significantly associated with recurrence or survival. Membrane EGFR over-expression in resected pancreatic cancer patients was associated with worse clinical outcomes than non-over-expression.
Introduction
Pancreatic cancer is the fourth leading cause of cancer death in United States with 36,800 deaths and 43,140 incident cases estimated in 2010 [1] . Despite therapy, the 5-year relative survival rate is approximately 6%. Due to relative lack of early disease-specific symptoms, only a minority of the patients present with surgically resectable disease. Even in patients who undergo pancreatectomy, the majority of the patients develop recurrence with the 5-year overall survival of only 22.5% [1] . Various genetic and molecular alterations are being investigated to understand the basis of the disease aggressiveness.
Epidermal growth factor receptor (EGFR) is a 170 kDaprotein belonging to ErbB family of transmembrane tyrosine kinase growth factor receptors [2] . It is over-expressed in wide variety of solid tumors including breast, colon, lung, and prostate cancer [3] . Activation of EGFR in tumors results in increased cell proliferation, reduced apoptosis, increased angiogenesis, increased motility, invasion, and metastasis [4] . The EGFR over-expression is observed in 30-90% of pancreatic cancers, assayed by immunohistochemistry techniques [5] . The cell membrane EGFR over-expression has been demonstrated to be associated with various clinicopathological features [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, the effect of membrane EGFR over-expression on clinical outcomes is not well defined. The association between cytoplasmic expression of EGFR and clinicopathologic features in patients with pancreatic cancer has been reported in only one prior study [13] .
In the current study, we investigated the association between cell membrane and cytoplasmic EGFR overexpression and pathologic features in patients with primary pancreatic cancer undergoing surgical resection. We also examined the role of EGFR over-expression in the prognosis of patients with resected pancreatic cancer.
Materials and methods

Patients
Ninety patients who underwent surgical resection for pancreatic cancer at Thomas Jefferson University from April 2008 to April 2010 were included in the study. All the cases were histologically diagnosed as ductal adenocarcinoma.
The patients who did not have any event (recurrence or death) were censored at the last date of follow-up. For pathologic and immunohistochemical evaluation, 10% neutral-buffered formalin-fixed and paraffin-embedded tissue blocks from surgically resected specimens were processed and 5-lm tissue sections were obtained. The tissue sections were stained using routine hemotoxylin and eosin for pathologic diagnosis. The study was approved by Institutional Review Board at Thomas Jefferson University.
Immunohistochemistry
Immunohistochemical staining for EGFR was performed on a total of 90 cases using the EGFR PharmDx TM kit (Dako). Specimens were evaluated for both cytoplasmic and membranous immunostaining by a pathologist blinded to the results at Thomas Jefferson University Hospital. Cytoplasmic over-expression was considered positive if EGFR expression was noted in the cytoplasm in C10% of tumor cells (Fig. 1) . Cell membrane EGFR staining was divided into four categories based on intensity and completeness of staining as follows: 0 (no membrane staining or membrane staining in less than 10% of tumor cells), 1? (incomplete membrane staining in C10% of cells), 2? (complete, weak or moderate membrane staining in C10% of cells), and 3? (complete, strong staining in C10% of cells) (Fig. 2) . Scores of 2? and 3? were considered membranous EGFR over-expression.
Statistical analysis
Descriptive statistics were initially used to characterize the cohort. Chi-square test was used to determine the association between EGFR over-expression and pathologic features. Proportional hazard regression analyses were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier survival curves, and differences in survival were tested using logrank tests. The two-sided P-value of 0.05 was used for statistical significance. All statistical analyses were done using SAS statistical software (SAS Institute, Inc., Cary, NC). Table 1 describes the demographic and pathologic features of the 90 patients of this study. The median age of the study cohort was 68 years (Range: 37-92 years). Thirty-seven (41.1%) patients were females, and 53 (58.9%) patients were males. The number of patients with AJCC stages I, II, III, and IV were 8 (9.2%), 79 (87.8%), 1 (1.1%), and 2 (2.2%), respectively. Seventy-seven patients underwent pylorus-preserving pancreaticoduodenectomy, and 13 patients underwent distal pancreatectomy. Sixty-seven (74.4%) patients underwent R0 resection. Cell membrane EGFR over-expression was observed in 51 (56.7%) patients. Sixty-four (71.1%) patients had cytoplasmic EGFR over-expression. The relationship between EGFR expression and pathologic features is summarized in Table 2 . The association between cell membrane EGFR over-expression and lymph node positivity was statistically significant (P = 0.03). No significant association of cell membrane EGFR over-expression was found with tumor grade, local invasion, margin positivity, vascular invasion, perineural invasion, or overall stage. For cytoplasmic EGFR over-expression, statistically significant association was observed with positive margin only (P \ 0.01).
Results
The median PFS and OS for the study cohort were 11.8 months and 17.1 months, respectively. The median follow-up time was 15.5 months. Fifty-two (58%) patients had either recurrence or death during the study follow-up. Histological grade, lymphovascular invasion and stage were significantly associated with survival. Figures 3 and 4 demonstrate the Kaplan-Meier PFS and OS curves stratified by membrane EGFR over-expression, respectively. Membrane EGFR over-expression was associated with statistically significant shorter PFS (median PFS: 10.7 months vs. 17.0 months, P = 0.02). The median OS for patients with cell membrane EGFR over-expression was also much shorter than the OS in patients without EGFR over-expression (median OS: 15.9 months vs. 25.3 months, P = 0.08), but this difference was not statistically significant, likely due to the small patient numbers (Table 3) . For recurrence and death, the HR for patients with cell membrane EGFR over-expression (when compared to no EGFR over-expression) was 1.97 (95% CI: 1.09-3.55) and 1.82 (0.92-3.62), respectively. Cytoplasmic EGFR over-expression did not correlate with PFS (median PFS: 11.7 months vs. 14.4 months, P = 0.30). The corresponding HR was 1.39 (0.74-2.61) without significant difference in survival between patients with or without cytoplasmic EGFR staining (P = 0.72). The median OS was 17.1 months in patients with cytoplasmic EGFR overexpression and 22.6 months in patients without EGFR over-expression (HR: 1.13; 95% CI: 0.57-2.27).
Discussion
Few retrospective studies have reported the relationship between EGFR over-expression and clinical outcomes in patients with pancreatic cancer [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Membrane EGFR over-expression has been demonstrated to be associated with higher stage and more aggressive tumors [12, 16] . However, the effect of EGFR over-expression on recurrence and survival in patients with pancreatic cancer remains unclear. Only three out of ten studies reported significantly worse survival in patients with membrane EFGR over-expression than without it (Table 4 ) [6] [7] [8] . In the current study, the resected pancreatic cancer patients with membrane EGFR over-expression had worse clinical outcomes. The PFS was significantly shorter, and there was trend toward poorer survival with membrane EFGR overexpression. There was significant association between lymph node involvement and membrane EGFR overexpression.
To our knowledge, this is only the second study to evaluate the cytoplasmic EGFR over-expression in resected pancreatic cancer patients. In the previous study, patients with cytoplasmic EGFR over-expression had shorter overall survival [13] . However, in our study, we did not find any statistically significant difference in recurrence or survival in relation to cytoplasmic EGFR over-expression. The cytoplasmic staining of EGFR has been demonstrated to be associated with a poor prognosis in patients with thyroid carcinoma and lung carcinoma [17, 18] . EGFR is internalized after the interaction with the ligand and completion of growth stimulatory signals and is subsequently degraded in lysosmal compartment. Thus, cellular localization pattern of EGFR may be of clinicopathologic significance, and its role as a prognostic and predictive marker needs to be further evaluated. Membrane EGFR expression is associated with poorer prognosis in head and neck, ovarian, cervical, bladder, esophageal, breast, colorectal, and gastric cancers [3] . EGFR plays an important role in the growth of various human cancers including pancreatic cancer [9] . The co-expression of EGFR and its ligand may function as an autocrine loop to constantly stimulate cell proliferation, and blockade of EGFR activity has been shown to decrease the growth and metastases of human pancreatic tumor xenografts and enhance the antitumor activity of gemcitabine [2, 19, 20] . Erlotinib, a small molecule EGFR-specific tyrosine kinase inhibitor, has been demonstrated to provide modest survival benefit in patients with locally advanced or metastatic pancreatic cancer [21] . However, cetuximab, a monoclonal EGFR antibody did not improve survival in patients with advanced pancreatic cancer [22] . In neither of these studies, membrane EGFR expression predicted tumor response to targeted therapy. Cytoplasmic EGFR expression was not reported. This suggests that in advanced stage pancreatic cancer patients, membrane EGFR expression is not a predictive marker for response to erlotinib or cetuximab. The role of both membrane and cytoplasmic EGFR expression in the adjuvant setting still needs to be examined.
Despite some recent advances in medical treatment, the prognosis of patients with pancreatic cancer remains dismal. Surgery has curative potential, but most of the patients present with an advanced, unresectable stage. Further, majority of patients with resected pancreatic cancer recur, even with adjuvant treatment. It is important to develop molecular markers that can predict clinical outcomes. This may help to direct more aggressive approaches in high-risk patients. We think that future clinical trials involving EGFR inhibitors should incorporate systematic evaluation of both cytoplasmic and membrane EGFR expression, especially in adjuvant setting. 
